Related Experiment Video
Updated: Jul 15, 2026
Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility
Published on: April 13, 2017
The role of microglia in the development of diabetic retinopathy and its potential clinical application
Tingting Lu1, Jiameng Shang1, Shengdan Pu1
1The First Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.
Abstract:
Lately, research on the function of microglia in diabetic retinopathy (DR) is becoming increasingly focused. Microglia are immune cells that dwell in the central nervous system and are crucial to the pathophysiology of DR. According to studies, a hyperglycemic environment can activate microglia, bringing them out of a resting state to an active state. This allows them to release a variety of inflammatory factors and chemokines, which can then cause retinal inflammatory reactions. When it comes to angiogenesis in DR, activated microglia release a variety of angiogenic substances, such as vascular endothelial growth factor (VEGF), to create aberrant new blood vessels. Moreover, microglia contribute to the retina's oxidative stress process by generating and releasing reactive oxygen and nitrogen-free radicals, which exacerbates retinal damage. Researchers have proposed a variety of strategies for the activation of microglia and the inflammatory response it triggers. By inhibiting the excessive activation of microglia and reducing the release of inflammatory factors, the inflammatory response and damage to the retina can be alleviated. Drugs that interfere with retinal microglia can also be used to regulate vascular damage and inhibit the formation of new blood vessels. In addition, antioxidants are used to remove reactive oxygen and free radicals, reduce oxidative stress levels, and protect retinal cells. These therapeutic strategies aim to achieve the purpose of treating DR by regulating the function of microglia. Thus, we highlight the possibility that therapy aimed at microglia could offer fresh ideas for treating DR.
Insights
Microglia, immune cells in the brain, drive diabetic retinopathy (DR) by releasing inflammatory factors and promoting abnormal blood vessel growth. Targeting microglia offers a promising new therapeutic strategy for DR treatment.
Area of Science:
- Neuroscience
- Ophthalmology
- Immunology
Background:
- Microglia are central nervous system immune cells implicated in diabetic retinopathy (DR) pathophysiology.
- Hyperglycemia activates microglia, leading to the release of inflammatory mediators and chemokines, causing retinal inflammation.
- Activated microglia contribute to DR by releasing vascular endothelial growth factor (VEGF), promoting aberrant angiogenesis and oxidative stress.
Purpose of the Study:
- To review the role of microglia in the development and progression of diabetic retinopathy.
- To explore therapeutic strategies targeting microglial activation and inflammatory responses in DR.
- To highlight the potential of microglial-focused therapies for DR treatment.
Main Methods:
- Literature review of studies investigating microglial function in diabetic retinopathy.
- Analysis of mechanisms by which microglia contribute to DR pathogenesis, including inflammation, angiogenesis, and oxidative stress.
- Evaluation of proposed therapeutic interventions aimed at modulating microglial activity.
Main Results:
- Microglial activation in a hyperglycemic environment releases inflammatory factors, exacerbating retinal inflammation.
- Activated microglia promote aberrant angiogenesis in DR through the release of factors like VEGF.
- Microglia contribute to oxidative stress in the retina, worsening cellular damage.
Conclusions:
- Inhibiting excessive microglial activation and reducing inflammatory factor release can alleviate DR-related retinal damage.
- Therapeutic strategies targeting retinal microglia, including specific drugs and antioxidants, show potential for regulating vascular damage and treating DR.
- Modulating microglial function represents a novel therapeutic avenue for managing diabetic retinopathy.
Related Concept Videos
01:27Diabetic Retinopathy
01:28Diabetic Nephropathy